Literature DB >> 6120817

Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro.

G Tybring, C von Bahr, L Bertilsson, H Collste, H Glaumann, M Solbrand.   

Abstract

The epoxidation of carbamazepine (CBZ) and the hydration of the primary epoxide metabolite was studied in microsomes isolated from ten human livers. To study the epoxide hydrolase activity a high-performance liquid-chromatographic method was developed for the analysis of dihydro-CBZ-trans-diol. There was a pronounced variation between the specimens in the activity of both enzymes. There appeared to be a positive correlation between the activity of the two enzymes. In rats pretreated with either CBZ or phenobarbital for 4 days, the microsomal epoxidation of CBZ was induced. The epoxide hydrolase activity was also increased, although less so than in epoxidation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6120817

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Metabolic interaction between imipramine and carbamazepine in vivo and in vitro in rats.

Authors:  W Daniel; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

2.  Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro.

Authors:  R J Riley; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 3.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

4.  Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.

Authors:  D K Robbins; P J Wedlund; R Kuhn; R J Baumann; R H Levy; S L Chang
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 5.  Genetic factors in the predisposition to drug-induced hypersensitivity reactions.

Authors:  Munir Pirmohamed
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

6.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

7.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats.

Authors:  W Daniel; L Janczar; L Danek; W Legrum; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

10.  Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey.

Authors:  P J Wedlund; I H Patel; R H Levy
Journal:  J Pharmacokinet Biopharm       Date:  1982-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.